<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5213</td>
<td>Highlights from Recent Cancer Literature</td>
<td></td>
</tr>
<tr>
<td>5215</td>
<td>Roles for Innate Immunity in Combination Immunotherapies</td>
<td>Kelly D. Moynihan and Darrell J. Irvine</td>
</tr>
<tr>
<td>5228</td>
<td>Targeting a Single Alternative Polyadenylation Site</td>
<td>Jamie L. Van Etten, Michael Nyquist, Yingming Li, Rendong Yang, Yeung Ho, Rachel Johnson, Olivia Ondigi, Daniel F. Voytas, Christine Henzler, and Scott M. Dehm</td>
</tr>
<tr>
<td>5236</td>
<td>Loss of Igf2 Gene Imprinting in Murine Prostate</td>
<td>Nathan A. Darnaschke, Bing Yang, Sachin Bhusari, Mei Avilla, Weixiong Zhong, Michael L. Blute Jr, Wei Huang, and David F. Jarrard</td>
</tr>
<tr>
<td>5248</td>
<td>PR2C-Mediated Transcriptomic Alterations at the Embryonic Stage Govern Tumorigenesis and Clinical Outcome in MYCN-Driven Neuroblastoma</td>
<td>Shoma Tsubota, Satoshi Kishida, Tepppei Shimamura, Miki Ohira, Satoshi Yamahita, Dongliang Cao, Shinichi Kyonari, Toshikazu Ushijima, and Kenji Kadowaki</td>
</tr>
<tr>
<td>5259</td>
<td>Aneuploid Cell Survival Relies upon Sphingolipid Homeostasis</td>
<td>Yun-Chi Tang, Hui Yuwen, Kaiying Wang, Peter M. Bruno, Kevin Bullock, Amy Deik, Stefano Santaguida, Marianna Trakala, Sarah J. Pfau, Na Zhong, Tao Huang, Lan Wang, Clary B. Clish, Michael T. Hemann, and Angelika Amon</td>
</tr>
<tr>
<td>5260</td>
<td>JCAD Promotes Progression of Nonalcoholic Steatohepatitis to Liver Cancer by Inhibiting LATS2 Kinase Activity</td>
<td>Juan Ye, Tian-Sheng Li, Gang Xu, Yi-Ming Zhao, Ning-Ping Zhang, Jia Fan, and Jian Wu</td>
</tr>
</tbody>
</table>

Précis: Precis statements for each article are provided, summarizing the research findings and implications.
### Table of Contents

#### TUMOR AND STEM CELL BIOLOGY

**5301** Nuclear FAK and Runx1 Cooperate to Regulate IGFBP3, Cell-Cycle Progression, and Tumor Growth  
Marta Canel, Adam Byron, Andrew H. Sims, Jessy Cartier, Hitesh Patel, Margaret C. Frame, Valerie G. Brunton, Bryan Serrels, and Alan Serrels  
*Précis:* These findings enhance understanding of the basic biology underlying ongoing clinical trials of FAK inhibitors for cancer therapy.

**5313** HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas  
Mianen Sun, Pan Tong, Wen Kong, Bajun Dong, Yiran Huang, In Young Park, Lijun Zhou, Xiao De Liu, Zhiyong Ding, Xuesong Zhang, Shanshan Bai, Peter German, Reid Powell, Quan Wang, Xuefei Tong, Nizar M. Tannir, Surena F. Matin, W. Kimryn Rathmell, Gregory N. Fuller, Ian E. McCutcheon, Cheryl L. Walker, Jing Wang, and Eric Jonasch  
*Précis:* These findings provide new insights into key epigenetic events, which drive an unusual type of kidney tumor, where additional loss of TP53 function promotes poor prognosis.

**5327** MRE11 Promotes Tumorigenesis by Facilitating Resistance to Oncogene-Induced Replication Stress  
Elizabeth Spehalski, Kayla M. Capper, Cheryl J. Smith, Mary J. Morgan, Maria Dinkelmann, Jeffrey Buis, JooAnn M. Sekiguchi, and David O. Ferguson  
*Précis:* New insights into how a DNA repair complex can promote tumorigenesis suggest new approaches to selectively improve cancer cell killing.

**5339** Chromatin-Associated Protein SIN3B Prevents Prostate Cancer Progression by Inducing Senescence  
Anthony J. Bainor, Fang-Ming Deng, Yu Wang, Peng Lee, David J. Cantor, Susan K. Logan, and Gregory David  
*Précis:* These results suggest a tumor suppressor function for SIN3B in prostate cancer, with potential implications for the use of SIN3B and its target genes as candidate diagnostic markers to distinguish indolent from aggressive disease.

**5349** Oncogenic KRAS and p53 Loss Drive Gastric Tumorigenesis in Mice That Can Be Attenuated by E-Cadherin Expression  
Jacob E. Till, Changhwan Yoon, Bang-Jin Kim, Kerry Roby, Prince Addai, Evan Jonokuchi, Laura H. Tang, Sam S. Yoon, and Sandra Ryecom  
*Précis:* These findings describe the first autochthonous mouse model of gastric adenocarcinoma that can recapitulate the metastatic processes that occur widely in patients.

**5360** S100A4 Is a Biomarker and Regulator of Glioma Stem Cells That Is Critical for Mesenchymal Transition in Glioblastoma  
Kin-Hoe Chow, Hee Jung Park, Joshy George, Reiko Yamamoto, Andrew D. Gallup, Joel H. Graber, Yuanxin Chen, Wen Jiang, Dennis A. Stein, Eric G. Neilson, Betty Y.S. Kim, and Kyuson Yun  
*Précis:* These findings demonstrate the role of S100A4 in glioblastoma as a regulator of the stemness and mesenchymal transition.

#### THERAPEUTICS, TARGETS, AND CHEMICAL BIOLOGY

**5374** Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells  
Victor A. Gall, Anne V. Philips, Na Qiao, Karen Clise-Dwyer, Alexander A. Perakis, Mao Zhang, Gay T. Clifton, Pariya Sukhumalchandra, Qing Ma, Sanghee M. Reddy, Dihua Yu, Jeffrey J. Molldrem, George E. Peoples, Gheath Alatrash, and Elizabeth A. Mittendorf  
*Précis:* These findings describe a potential mechanism by which patients treated with trastuzumab, followed by vaccination with a CD8 T-cell-eliciting vaccine, may experience a robust antitumor immune response.

**5384** Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells  
Chien-Hsing Chang, Yang Wang, Rongxiu Li, Diane L. Rossi, Donglin Liu, Edmund A. Rossi, Thomas M. Cardillo, and David M. Goldenberg  
*Précis:* Bispecific antibodies that can bind a T cell along with a tumor cell antigen and redirect the T cell to the tumor can leverage the therapeutic benefits of PD1 blockade, an important present goal in immuno-oncological treatment of solid tumors.

**5395** Mitotic Vulnerability in Triple-Negative Breast Cancer Associated with LIN9 Is Targetable with BET Inhibitors  
*Précis:* These findings demonstrate that BET inhibitors can target genes such as LIN9, whose chromatin lacks super-enhancer-associated epigenetic marks.
INTEGRATED SYSTEMS AND TECHNOLOGIES

5409 Integrating Models to Quantify Environment-Mediated Drug Resistance
Noemi Picco, Erik Sahai, Philip K. Maini, and Alexander R.A. Anderson
Précis: Quantification of the environmental contribution to drug resistance reveals that tumor heterogeneity altering treatment dynamics can be exploited for therapeutic gain.

CLINICAL STUDIES

5419 Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing
Précis: This milestone study showcases the power of genomic profiling of tumors by next-generation sequencing of circulating tumor DNA, as illustrated in the first large and diverse cohort of cancer patients, including for difficult-to-biopsy tumors.

CORRECTION

5438 Evolution of Cancer Stem-like Cells in Endocrine-Resistant Metastatic Breast Cancers Is Mediated by Stromal Microvesicles

AC icon indicates Author Choice
For more information please visit www.aacrjournals.org
ABOUT THE COVER

JCAD and LATS2 were stained immunohistochemically with specific primary antibodies and secondary antibodies labeled with Alexa-488 (green for JCAD) or Alexa-594 (red for LATS2). The nucleus was visualized by DAPI staining in blue. JCAD is overlaid with LATS2 in the proximity of the nucleus and appears in yellow. For details, see article by Ye and colleagues on page 5287.
Cancer Research

77 (19)

Cancer Res 2017;77:5213-5438.

Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/77/19

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.